Latest Breaking News On - Kurma partners - Page 2 : comparemela.com

Neuraxpharm: Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

Neuraxpharm: Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaFrance generalUnited statesLaboratorios lesviFanny mochelThomas dierksKaren harrisonMarc martinellPrnewswire neuraxpharm groupNeuraxpharm groupLeukodystrophy charityRoche venture fundReference centerNeuraxpharm pharmaceuticalsMinoryx therapeuticsRare disease day

Rare Disease Day 2024 - Call For Greater Awareness Of X-Linked Adrenoleukodystrophy And Cerebral Adrenoleukodystrophy - Special Film Launched

Rare Disease Day 2024 - Call For Greater Awareness Of X-Linked Adrenoleukodystrophy And Cerebral Adrenoleukodystrophy - Special Film Launched
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalComunidad autonoma de catalunaLaboratorios lesviKaren harrisonThomas dierksMarc martinellFanny mochelLeukodystrophy charityNeuraxpharm groupRoche venture fundNeuraxpharm pharmaceuticalsReference centerPrnewswire neuraxpharm groupMinoryx therapeuticsRare disease day

Samsung Biologics and LegoChem enter ADC development deal

Samsung Biologics has entered into a strategic partnership with LegoChem Biosciences to advance ADC programmes aimed at treating solid tumours.

Legochem biosciencesSamsung biologicsDrug administrationSamsung life science fundSamsung biologicLegochem bioscienceInvestigational new drugYong zu kimChem biosciencesKurma partnersKurma partnerJohn rim

Vivet Therapeutics receives EUR 4 9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis

Vivet Therapeutics receives EUR 4 9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalJean philippe combalGloria gonzalezStefan klotterGloria gonzalez aseguinolazaPfizer incFrance health innovation planFrench health innovationNovartis venture fundNational research agencyAgency for ecological transitionRoche venture fundFrench governmentChief scientific officerVivet therapeuticsWilson disease

Vivet Therapeutics Receives EUR 4 9M Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

France generalJean philippe combalGloria gonzalez aseguinolazaRoche venture fundFrance health innovation planNovartis venture fundPfizer incVivet therapeuticsFrench governmentColumbus venture partnersYsios capitalKurma partners